Article

Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation.

Journal of Ocular Pharmacology and Therapeutics (Impact Factor: 1.42). 07/2006; 22(3):155-9. DOI: 10.1089/jop.2006.22.155
Source: PubMed

ABSTRACT The aim of this study was to compare the anti-inflammatory activities of ketorolac tromethamine 0.4% and 0.1%; diclofenac sodium 0.1%; and loteprednol etabonate 0.5% suspension in an animal model of ocular inflammation.
An ocular inflammatory response was induced in New Zealand White rabbits by the intravenous (i.v.) administration of 10 microg/kg lipopolysaccharide (LPS). In study animals, 1 eye was treated topically with 50 microL of study medication (n = 8 animals per drug) and the other eye was treated topically with a 50-microL vehicle (buffered saline). In control animals (n = 8), both eyes were treated with vehicle. All animals were treated twice: 2 h and 1 h before LPS challenge. The breakdown of the blood-aqueous barrier in the anterior chamber was measured by fluorophotometry (FITC-dextran 30 mg/kg, i.v. given immediately after LPS challenge). Aqueous prostaglandin E(2) (PGE(2)) levels were measured using an enzyme-linked immunosorbent assay (ELISA) immunoassay.
Ketorolac 0.4% resulted in a nearly complete inhibition of endotoxin-induced increases in FITC-dextran and PGE(2) synthesis (P < 0.001 vs. vehicle). Diclofenac 0.1% had much less of an effect on these parameters (P < 0.01 vs. ketorolac 0.4%). Loteprednol 0.5% was no more effective than vehicle at inhibiting increases in FITC-dextran.
Ketorolac has greater anti-inflammatory effects than diclofenac and loteprednol.

0 Bookmarks
 · 
52 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple, rapid, sensitive, and accurate extractive spectrophotometric method has been developed for the determination of seven nonsteroidal anti-inflammatory drugs (NSAIDs)--namely diclofenac sodium, ibuprofen, indomethacin, ketoprofen, ketorolac tromethamine, mefenamic acid, and naproxen-in pure forms as well as their pharmaceutical dosage forms (tablets, capsules, effervescent granules, syrups, oral drops, ampules, eye drops, gels, and suppositories). The method depends on the formation of an intensely colored ion-pair complex between the acidic drug and methylene blue in alkaline medium. The complex is stable and extractable into methylene chloride. All parameters were optimized. Beer-Lambert's law was obeyed in concentrations ranging from 0.04 to 9 microg/mL. Statistical analysis of the calibration data was carried out, and correlation coefficients were in the range from 0.9996 to 0.9998. The developed method was fully validated according to International Conference on Harmonization guidelines, and complied with U.S. Pharmacopeia guidelines. The proposed method was applied to the analysis of the investigated drugs in their pharmaceutical formulations, and good recoveries were obtained. The results obtained were compared with those of reported and official methods, and no significant differences were found with t- and F-tests. Interference effects of some compounds usually present in combination with NSAIDs were studied, and the tolerance limits of these compounds were determined.
    Journal of AOAC International 07/2013; 96(4):737-44. · 1.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A range of diclofenac salts was prepared with a variety of alkyl, hydroxyalkyl and alkyl hydroxyalkyl linear amines, and characterized by thermal analysis (DSC, TGA, and HSM). Another seven similar salts, previously described, were also prepared for a more careful analysis and comparison. The aim of this paper is a deeper knowledge of this class of compounds, previously poorly examined and that have, on the contrary, proved to offer complex situations in the solid state, as resulted by thermal analysis. The whole class of these salts presents a variety of behaviours, ranging from the formation of hydrates to polymorphs and hydrate polymorphs in the solid state. The salts with diethanolamine, triethanolamine, N-ethyl monoethanolamine and TRIS bases crystallize anhydrous. All the salts demonstrated thermal instability at temperature above the melting point, showing a dramatic loss of weight. In each case the TGA profile indicates that it corresponds to the base content inside the salt: this event is associated with a broad endotherm in the DSC thermogram that follows or overlaps with that of the melting endotherm. Prolonged heating in the oven of salts with very volatile amines causes decomposition, even at low temperatures, leaving the starting acidic diclofenac as residue. Different phases, in the case of polymorphs, were revealed, registering melting/re-crystallization by hot stage microscopy, as in the case of the salts with triethylamine and N-methyl monoethanolamine; while in the case of the salt with monoethanolamine evidence was obtained by means of DSC. The relationship between the structure of the starting bases and solid-state nature of these diclofenac salts studied is briefly discussed.
    Thermochimica Acta 11/2007; 464(s 1–2):65–74. · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ketorolac tromethamine ophthalmic solution, a NSAID, demonstrated analgesic activity when administered systemically. The original 0.5% formulation was shown to reduce inflammation and pain, as well as general discomfort after cataract and keratorefractive surgery. A reformulation that contains 20% less active ingredient than the original was approved for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine 0.4% is as effective as ketorolac tromethamine 0.5% to control inflammation after cataract surgery (including prevention of cystoid macular edema) as shown in different clinical trials. Comparisons to other NSAIDs for pain control after keratorefractive procedures, such as laser-assisted in situ keratomileusis and photorefractive keratectomy, have also been reported. The purpose of this study was to review the action of ketorolac tromethamine 0.4% in the relief of eye pain and inflammation after cataract extraction and keratorefractive surgery.
    Expert Review of Ophthalmology 09/2009; 4(5):461-468.